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Disease case definitions are important instruments for clinical care, interventional research, and 
surveillance. In light of this, it is concerning that the current case definitions for tuberculosis (TB) 
remain underscored by the classic paradigm of binary states of latent infection and active disease, 
with a stepwise, linear transition under which symptoms, bacteriological positivity and disease 
pathology are assumed to emerge broadly together (figure, top row).1  This has resulted in a reliance 
on symptom screening to distinguish these two states. However, in recent prevalence surveys 40-
79% of bacteriologically-positive TB occurs in absence of patient-recognised TB symptoms. 2 Rather 
than explicitly addressing this discordance, TB case definitions are often ambiguous with regard to 
TB symptoms, or internally inconsistent.  
 
We propose a new perspective on the case definition of pulmonary TB, one that resolves the current 
ambiguity of TB symptoms and recognises the presence and dynamics of subclinical TB. 3 Under this 
paradigm, individuals with subclinical TB, also referred to as the ‘Walking well’, have M. tuberculosis 
(Mtb) bacteriologically-positive pulmonary lesions and are thus able to transmit Mtb intermittently 
or persistently through symptoms they are not aware of, don’t acknowledge, or attribute to 
alternative conditions (figure, middle row). 4 Crucially, some of these individuals may never advance 
to clinical TB disease, but instead persist at subclinical level for an unknown period, or regress and 
self-cure (figure, bottom row).    
 
Allowing for case definitions that recognise distinct disease phenotypes has wide precedent. For 
example, both HIV and malaria have well-established definitions for infectious, but not clinically ill 
individuals (e.g. people living with HIV 6 and (sub)patent malaria infections7). In TB, the implications 
of current practices are wide ranging. Below we highlight consequences in the areas of clinical care, 
trials as well as TB surveillance and policy, and suggest potential actions to facilitate resolution.  
 
Currently all individuals diagnosed with drug-sensitive TB disease receive the same six month, four-
drug treatment regimen. While this simplification has enabled the roll-out of DOTS, which has saved 
millions of lives,8 it ignores the difference in treatment requirements that may exist between 
individuals diagnosed passively based on self-reported symptoms and those actively identified in 
absence of any clinical signs. Historically, treatment regimens have differed depending on clinical 
severity, and trials of bacteriologically-negative individuals with minimal Xray lesions showed similar 
efficacy of four months treatment as six months treatment in bacteriologically-positive individuals.9  
Explicit differentiation in the case definition may therefore enable development of trials for more 
personalized, and potentially shorter regimens.  
 
The TB case definitions used in research, trials in particular, can be ambiguous with regard to the 
requirement of symptoms, and are often inconsistent between entry and follow-up. As a 
consequence, disease prevention trials enrolling individuals based on absence of symptomatic 
disease only may underestimate the efficacy of the intervention if the initial period during which 
incident cases of TB disease are not counted is short. 10 In addition, taking bacteriologically-positive 
symptomatic TB disease as the primary outcome will miss subclinical TB, which not only limits the 
trial’s statistical power but also its ability to differentiate the effect of the intervention on preventing 
or detecting subclinical versus classic clinical TB. For example, it will be important to understand 
whether a candidate TB vaccine protects against any disease (thus interrupting transmission) or only 
against clinically overt disease, leaving subclinical cases to sustain transmission. We note that during 
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the recent M72/AS01E trial all endpoints were based on clinical presentation, thus providing limited 
insight as to where in the development of disease the vaccine has an effect. 11 We propose that case 
definitions in TB trials are expanded to enable detection of differential effect of the intervention on 
subclinical and clinical TB disease. One option is to complete follow-up with a symptom-agnostic 
culture-based test in all participants, which would have resource implications, but would also 
identify subclinical TB, and enable the required analyses. Here, regulatory agencies could drive 
change, and specify at what point in development a product’s impact needs to be evaluated on the 
full spectrum of bacteriological positive TB, rather than the symptomatic subset, e.g. at phase 2B. 
 
On a policy level, there are inconsistencies in the case definitions used to estimate the incident 
burden of TB. For example, for many high-burden countries, incidence is extrapolated from 
prevalence surveys, which include both (asymptomatic) subclinical and (symptomatic) clinical 
bacteriologically-positive TB,2 whereas for others it is primarily based on notifications 8 which 
predominantly reflect individuals who self-reported to clinics with symptomatic TB. Since in most 
settings the incidence to notification ratio (i.e. the ‘case detection rate’) is used to estimate 
programme performance, this inconsistency in case definition is problematic. In addition, global and 
National TB programmes should acknowledge that up to 80% of individuals with likely infectious TB 
present in their population will not be detected by the symptom-dependent case-finding strategies 
which still dominate TB policy.12 By recognising that bacteriologically-positive and symptomatic TB 
often overlap only partially, a set of symptom-agnostic case-finding approaches can be developed 
that are potentially effective. Such changes should also be reflected in what surveillance systems 
report, e.g. mode of detection, and presence of clinical symptoms to enable more refined analysis of 
notification data and programme performance. Guidance in this area falls to policy bodies, in 
particular the Global TB Department at WHO, which should also ensure that sufficient specificity is 
retained to avoid an increase in false-positive TB diagnoses. 13  
 
Even if our proposed changes to distinguish symptomatic and non-symptomatic disease are 
adopted, many challenges will remain. For example, the detected size of the subclinical TB 
population will vary depending the sampling approach, timeframe and the microbiological 
techniques used.14 Yet if we are to achieve meaningful reduction of the burden of TB in our lifetime, 
we need to interrupt transmission, which will require addressing all bacteriologically-positive TB, 
including subclinical.  Recognising this disease state in our TB case definitions, and removing the 
current ambiguity, will provide a better understanding of current epidemiology and enable more 
effective control policy. We hope our proposals can advance discussions and enable much needed 
progress.  
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Figure: Progression of individual after initial Mtb infection 
 
Progression of individuals after infection with Mycobacterium tuberculosis and associated TB case 
definitions. a) Classic TB case definition, which assumes an individual’s incubation and pre-infectious period 
simultaneously transition into clinical disease and becoming infectious. b) Addition of a subclinical or ‘Walking 
well’ stage leads to infectious period now preceding clinical disease. c): Addition of non-progression or self-
cure from subclinical stage will introduce a discrepancy between measured prevalence and estimated 
incidence. Mtb = Mycobacterium tuberculosis 
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